Zhenfeng Duan

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay
    Michiro Susa
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Biomol Screen 15:287-96. 2010
  2. ncbi Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology and Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Cancer Res 18:4580-8. 2012
  3. ncbi CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 63:681-9. 2009
  4. ncbi Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Jackson Building, Boston, Massachusetts 02114, USA
    Mol Cancer Ther 8:2122-30. 2009
  5. ncbi NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 4:e7415. 2009
  6. ncbi Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, 100 Blossom St Jackson 1106, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 63:1121-9. 2009
  7. ncbi Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
    Mol Cancer Ther 7:2377-85. 2008
  8. ncbi Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Orthop Res 28:746-52. 2010
  9. ncbi 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells
    Zhenfeng Duan
    Department of Hematology Oncology, Massachusetts General Hospital, 100 Blossom St Jackson 1008, Boston, MA 02114, USA
    Mol Pharmacol 72:1137-45. 2007
  10. ncbi Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Lett 293:220-9. 2010

Collaborators

Detail Information

Publications56

  1. ncbi Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay
    Michiro Susa
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Biomol Screen 15:287-96. 2010
    ..The use of NSC77037 to restore sensitivity to chemotherapy or to prevent resistance could be a potential treatment strategy for cancer patients...
  2. ncbi Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology and Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Cancer Res 18:4580-8. 2012
    ..Identification of new targeted therapies is critical to improving the survival rate of patients with osteosarcoma. The goal of this study is to identify kinase based potential therapeutic target in osteosarcomas...
  3. ncbi CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 63:681-9. 2009
    ..Inhibition is likely achieved through multiple points within these pathways. In a model system of established acquired drug resistance, CCDO-Me is effective at partially reversing the drug-resistance phenotype...
  4. ncbi Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Jackson Building, Boston, Massachusetts 02114, USA
    Mol Cancer Ther 8:2122-30. 2009
    ..Our data suggest that inhibition of IGF-IR with PPP offers a novel and selective therapeutic strategy for ostosarcoma, and at the same time, PPP is effective at reversing the drug-resistant phenotype in osteosarcoma cell lines...
  5. ncbi NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 4:e7415. 2009
    ..To date, none of these attempts have yielded a tolerable and effective therapy to reverse MDR; thus, identification of new agents would be useful both clinically and scientifically...
  6. ncbi Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, 100 Blossom St Jackson 1106, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 63:1121-9. 2009
    ..The present study was performed to elucidate the relationship between the expression of ABCB1/MDR1 and ABCC1/MRP1 with resistance to either ET-743 or PM00104...
  7. ncbi Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
    Mol Cancer Ther 7:2377-85. 2008
    ..Finally, overexpression of PRP-4 in drug-sensitive cells could induce a modest level of drug resistance to paclitaxel, doxorubicin, and vincristine...
  8. ncbi Differential expression of microRNA (miRNA) in chordoma reveals a role for miRNA-1 in Met expression
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Orthop Res 28:746-52. 2010
    ..Our results demonstrate that some miRNAs are differentially expressed in chordoma and, in particular, miRNA-1 may have a functional effect on chordoma tumor pathogenesis...
  9. ncbi 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells
    Zhenfeng Duan
    Department of Hematology Oncology, Massachusetts General Hospital, 100 Blossom St Jackson 1008, Boston, MA 02114, USA
    Mol Pharmacol 72:1137-45. 2007
    ..Finally, SD-1008 may be a suitable prototype for further chemical modification and exploration as a therapeutic agent...
  10. ncbi Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Lett 293:220-9. 2010
    ..The development of more potent inhibitors that target PLK1 may open doors to a new range of anti-cancer strategies in osteosarcoma...
  11. ncbi Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines
    Zhenfeng Duan
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, MA, 02114, USA
    Cancer Chemother Pharmacol 55:277-85. 2005
    ..To identify genes involved in the paclitaxel resistance phenotype...
  12. ncbi SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation
    Zhenfeng Duan
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, and Chemical Biology Program, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA
    Clin Cancer Res 12:6844-52. 2006
    ..To discover novel inhibitors of the Stat3 signaling pathway, we designed a cell-based screening assay capable of identifying compounds that inhibit Stat3 nuclear translocation and activity...
  13. ncbi Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer
    Zhenfeng Duan
    Division of Hematology Oncology, Department of Pathology, and Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 12:5055-63. 2006
    ..To further clarify the significance of Stat3 activation in ovarian cancer, here we investigated the Stat3 expression and activation in ovarian cancer and ovarian cancer multidrug resistance cell lines...
  14. ncbi MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration
    Zhenfeng Duan
    Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Mol Cancer Ther 10:1337-45. 2011
    ..Restoring miR-199a-3p's function may provide therapeutic benefits in osteosarcoma...
  15. ncbi GBP1 overexpression is associated with a paclitaxel resistance phenotype
    Zhenfeng Duan
    Department of Hematology Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 57:25-33. 2006
    ..Our data suggest that increased expression of the GBP1 gene may play an important role in the development of multi-drug resistance (MDR)...
  16. ncbi MM-TRAG (MGC4175), a novel intracellular mitochondrial protein, is associated with the taxol- and doxorubicin-resistant phenotype in human cancer cell lines
    Zhenfeng Duan
    Department of Hematology Oncology, Massachusetts General Hospital, Jackson 1029, 70 Blossom Street, Boston, MA 02114, USA
    Gene 340:53-9. 2004
    ....
  17. ncbi Characterization and analysis of human chordoma cell lines
    Cao Yang
    Department of Orthopaedic Surgery, Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Spine (Phila Pa 1976) 35:1257-64. 2010
    ..An experimental study to investigate the characterization of 3 chordoma cell lines...
  18. ncbi Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines
    Zhenfeng Duan
    Department of Hematology/Oncology Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Cancer Res 9:2778-85. 2003
    ..These antigens, because of limited expression in normal tissues, may be suitable targets for immunotherapy and novel therapeutic strategies in the treatment of chemotherapy-resistant epithelial tumors...
  19. ncbi Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma
    Michiro Susa
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA
    PLoS ONE 5:e10764. 2010
    ..However, for patients who progress after chemotherapy, its effectiveness diminishes due to the emergence of multi-drug resistance (MDR) after prolonged therapy...
  20. ncbi Augmentation of therapeutic efficacy in drug-resistant tumor models using ceramide coadministration in temporal-controlled polymer-blend nanoparticle delivery systems
    Lilian E van Vlerken
    Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts 02115, USA
    AAPS J 12:171-80. 2010
    ..This strategy has tremendous potential for effective treatment of refractory disease in cancer patients...
  21. ncbi Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
    Keinosuke Ryu
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    BMC Cancer 10:187. 2010
    ....
  22. ncbi Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma
    Michiro Susa
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    BMC Cancer 9:399. 2009
    ....
  23. ncbi RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines
    Cao Yang
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 64:607-14. 2009
    ..To identify the apoptosis genes involved in the multidrug resistant phenotype of osteosarcoma...
  24. ncbi The kinase Mirk is a potential therapeutic target in osteosarcoma
    Cao Yang
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Carcinogenesis 31:552-8. 2010
    ..This highlights Mirk's potential to serve as a promising target for molecular therapy in the treatment of osteosarcoma...
  25. ncbi ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 4:e6967. 2009
    ..ET-743 and PM00104 exposure over sustained periods of treatment will result in the development of drug resistance, but the mechanisms which lead to resistance are not yet understood...
  26. ncbi A novel target for treatment of chordoma: signal transducers and activators of transcription 3
    Cao Yang
    Department of Orthopaedic Surgery, Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Mol Cancer Ther 8:2597-605. 2009
    ..In conclusion, the Stat3 pathway is constitutively activated in chordomas and the level of expression may serve as a predictor for prognosis. Blockade of the Stat3 pathway represents a potential strategy for future treatment...
  27. ncbi Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells
    Cao Yang
    Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Cancer Chemother Pharmacol 67:439-46. 2011
    ..To better understand the mechanisms of cytotoxicity and cell death induced by HDACI PCI-24781 in bone sarcoma cells...
  28. ncbi Multidrug resistant osteosarcoma cell lines exhibit deficiency of GADD45alpha expression
    Cao Yang
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Apoptosis 14:124-33. 2009
    ..These results suggest that GADD45alpha may play a role in drug-induced apoptosis, as well as multidrug resistance in osteosarcoma cells...
  29. ncbi Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles
    Harikrishna Devalapally
    Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA 02115, USA
    Clin Cancer Res 14:3193-203. 2008
    ....
  30. ncbi ROCK1 as a potential therapeutic target in osteosarcoma
    Xianzhe Liu
    Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Orthop Res 29:1259-66. 2011
    ..These findings suggest that knockdown of ROCK1 inhibits proliferation and induces apoptosis in osteosarcoma cell lines. ROCK1 may be a promising therapeutic target for the treatment of osteosarcoma patients...
  31. ncbi Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo
    Xianzhe Liu
    Department of Orthopaedic Surgery, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Anticancer Drugs 22:444-53. 2011
    ..Finally, in mouse osteosarcoma xenografts, BI 2536-treated mice had significantly smaller tumors compared with the control mice. These findings offer evidence of the potential role for targeting PLK1 in osteosarcoma therapy...
  32. ncbi Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells
    Zhenfeng Duan
    Department of Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Mol Cancer Ther 3:833-8. 2004
    ..These results indicate that siRNA targeted to ABCB1 can sensitize paclitaxel-resistant ovarian cancer cells in vitro and suggest that siRNA treatment may represent a new approach for the treatment of ABCB1-mediated drug resistance...
  33. ncbi Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study
    Eisuke Kobayashi
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, 100 Blossom St, Jackson 1115, Boston, MA 02114, USA
    Clin Orthop Relat Res 471:915-25. 2013
    ..However, it is unclear whether doxorubicin (Dox) can be delivered by nanotechnologic approaches...
  34. ncbi Combination of PI3K/mTOR inhibition demonstrates efficacy in human chordoma
    Joseph Schwab
    Department of Orthopedic Surgery, Section of Orthopedic Oncology, Sarcoma Research Laboratory, Massachusetts General Hospital, Boston, MA 02114, U S A
    Anticancer Res 29:1867-71. 2009
    ..PI-103 is a inhibitor of PI3K/AKT and mTOR activation. This study aims to determine whether the PI3K/mTOR pathway was active in chordomas and whether their inhibition could lead to decreased proliferation and increased apoptosis...
  35. ncbi Targeting hedgehog-GLI-2 pathway in osteosarcoma
    Wen Yang
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Orthop Res 31:502-9. 2013
    ..These findings suggest GLI-2 is required for osteosarcoma cell proliferation and survival. GLI-2 may be exploited as a therapeutic target for the treatment of osteosarcoma patients...
  36. ncbi Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer
    Zhenfeng Duan
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Med Chem 55:3113-21. 2012
    ..In conclusion, 11 and derivatives of this compound may hold therapeutic value in the treatment of MDR-dependent cancers...
  37. ncbi Cyclin G-associated kinase is necessary for osteosarcoma cell proliferation and receptor trafficking
    Michiro Susa
    Department of Orthopaedic Surgery, and SarcomaBiology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Mol Cancer Ther 9:3342-50. 2010
    ..In conclusion, our results suggest that osteosarcoma cell proliferation and survival are dependent on GAK. These findings may lead to the development of new therapeutic options for osteosarcoma...
  38. ncbi Activation of signal transducer and activator of transcription 3 (Stat3) pathway in osteosarcoma cells and overexpression of phosphorylated-Stat3 correlates with poor prognosis
    Keinosuke Ryu
    Department of Orthopedic Surgery, Massachusetts General Hospital, Center for Sarcoma and Connective Tissue Oncology, 55 Fruit St Jackson 1115, Boston, Massachusetts 02114, USA
    J Orthop Res 28:971-8. 2010
    ..Our results suggest that Stat3 may be a prognostic indicator and potential therapeutic target for osteosarcoma. Blocking the pathway of Stat3 may lead to develop new therapeutic strategies against osteosarcoma...
  39. ncbi Nanoparticles: a promising modality in the treatment of sarcomas
    Michiro Susa
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Pharm Res 28:260-72. 2011
    ..In this review, we will discuss the application of nanoparticles for improving the treatment of sarcoma patients...
  40. ncbi Biodistribution and pharmacokinetic analysis of Paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model
    Lilian E van Vlerken
    Department of Pharmaceutical Sciences, Northeastern University, Department of Orthopedic Surgery, Massachusetts General Hospital, Boston, Massachusetts 02115, USA
    Mol Pharm 5:516-26. 2008
    ..Overall, these results are highly encouraging for development of multifunctional polymer-blend nanoparticle formulations that can be used for temporal-controlled administration of two drugs from a single formulation...
  41. ncbi Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer
    Lara Milane
    Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts, United States of America
    PLoS ONE 6:e24075. 2011
    ....
  42. ncbi Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer
    Yuqi Guo
    Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Cancer Res 16:5759-69. 2010
    ..We then looked for enhancing paclitaxel sensitivity in multidrug-resistant ovarian cancer cell lines...
  43. ncbi Blockage of Stat3 with CDDO-Me inhibits tumor cell growth in chordoma
    Cao Yang
    Department of Orthopaedic Surgery, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Spine (Phila Pa 1976) 35:1668-75. 2010
    ..An experimental study to investigate the activation of Src/Stat3 pathways in chordomas and blockage of this pathway as a potential strategy for chordoma treatment...
  44. ncbi Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer
    Harikrishna Devalapally
    Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, MA 02115, USA
    Int J Cancer 121:1830-8. 2007
    ..The results of this study show that combination of PTX and CER in biodegradable polymeric nanoparticles can serve as a very effective therapeutic strategy to overcome drug resistance in ovarian cancer...
  45. ncbi Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells
    Lara Milane
    Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts 02115, USA
    Mol Pharm 8:185-203. 2011
    ....
  46. ncbi Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer
    Lilian E van Vlerken
    Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts, USA
    Cancer Res 67:4843-50. 2007
    ....
  47. ncbi Establishment and characterization of a novel chordoma cell line: CH22
    Xianzhe Liu
    Department of Orthopaedic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Orthop Res 30:1666-73. 2012
    ....
  48. ncbi High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes
    Edwin Choy
    Division of Hematology Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 118:2905-14. 2012
    ..The identification of new genes that are mutated in osteosarcomas is critical to developing a better understanding of the molecular pathogenesis of this disease and discovering new targets for therapeutic development...
  49. ncbi Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model
    Jiangyong Miao
    Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA
    Int J Cancer 123:2041-7. 2008
    ..The ability of ectopic hepsin to induce tumor growth in mice is abrogated by the mutation of 3 critical residues in the catalytic domain, thus implicating the enzymatic activity of hepsin in promoting tumor progression...
  50. ncbi Recurrent chromosomal copy number alterations in sporadic chordomas
    Long Phi Le
    Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 6:e18846. 2011
    ..Sporadic chordomas may rely on mechanisms other than copy number gain if they indeed exploit T/brachyury for proliferation...
  51. ncbi beta tubulin mutations are rare in human ovarian carcinoma
    Diana E Lamendola
    Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Anticancer Res 23:681-6. 2003
    ..CONCLUSION: This result suggests that mutations within exon four of human beta tubulin are rare in newly-diagnosed and recurrent paclitaxel resistant human ovarian cancer...
  52. ncbi Interleukin-6 signaling pathway in targeted therapy for cancer
    Yuqi Guo
    The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, PR China
    Cancer Treat Rev 38:904-10. 2012
    ..In this review, we detail the progress of the current understanding of IL-6 signaling pathway in cancer as well as an antibody targeted IL-6 therapy for human cancer...
  53. ncbi Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning
    Lara Milane
    Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA
    Cancer Cell Int 11:3. 2011
    ..abstract:..
  54. ncbi MicroRNA Involvement in Osteosarcoma
    Eisuke Kobayashi
    Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
    Sarcoma 2012:359739. 2012
    ..In this review, we summarize the current understanding of the roles that miRNAs play in OS, and highlight their potential as biomarkers or therapeutic targets...
  55. ncbi Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line
    Diana E Lamendola
    Division of Hematology/Oncology, Massachusetts General Hospital Boston 02114, USA
    Cancer Res 63:2200-5. 2003
    ..Such an analysis may be useful at defining candidate gene families involved in the early-drug resistance phenotype...
  56. ncbi Taxol-resistance-associated gene-3 (TRAG-3/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients
    Verena Materna
    Institute of Pathology, Charite Campus Mitte, Chariteplatz 1, 10117 Berlin, Germany
    Virchows Arch 450:187-94. 2007
    ..In summary, TRAG-3 was found to be a prognostic factor for the prediction of clinical outcome after the application of paclitaxel-based chemotherapy...